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TObjective: Bicuspid aortic valve, the most common congenital cardiac malforma-
tion, is caused by fusion of valve cushions at the onset of valvulogenesis. Although
its exact pathogenesis is still unclear, a genetic basis is appearing more and more
likely. Search for a potential candidate gene by reviewing semilunar valve morpho-
genesis led us to the ubiquitin fusion degradation 1–like gene (UFD1L), which is
highly expressed in the cardiac outflow tract during embryogenesis.
Methods: Aortic valves were collected during surgery from 39 patients with bicus-
pid aortic valve (mean age 56.8  18.1 years) and from 38 patients with tricuspid
aortic valve (mean age 61.7  16.1 years). Fluorescence in situ hybridization was
performed for detection of microdeletion, quantitative reverse transcriptase–
polymerase chain reaction to measure gene expression, and Western blotting to
analyze the amount of UFD1L gene product.
Results: No microdeletion was found in either group in the critical region of
chromosome 22 containing the UFD1L gene. UFD1L gene expression, however,
was significantly reduced in bicuspid aortic valve samples (median 787-fold)
relative to tricuspid aortic valve samples (median 10,887-fold, P  .001). The
amount of UFD1L gene product was also significantly diminished in bicuspid aortic
valve samples (3.9  2.6 vs 8.4  4.8 optical density units, P  .05).
Conclusion: Bicuspid aortic valve was associated with downregulation of UFD1L
gene expression, supporting the hypothesis that bicuspid aortic valve is a genetic
disorder, with the UFD1L gene as a potential candidate gene.
Bicuspid aortic valve (BAV) is the most common congenital cardiac malfor-mation, with an estimated incidence of 1% to 2% in the general population.1BAV not only contributes significantly to the cardiovascular health burden
but also poses a challenge to valve surgeons. Knowledge of the pathogenetic
mechanisms underlying BAV could help in stratification of treatment modalities.
Several family studies have found that anomalies of the left ventricular outflow tract,
including BAV, are inherited disorders2; their genetic basis, however, remains
obscure. Some recent reports suggest that BAV reflects a developmental defect
during embryogenesis.3-5 At the beginning of valvulogenesis, a population of cells
called neural crest cells migrate away from the neural fold and spread throughout
the embryo. These cells seem to play a crucial role in normal development of the
cardiac outflow tract and semilunar valves.6-8 The basic helix-loop-helix transcrip-
tion factor dHAND* is essential for survival of cells in neural crest–derived
ventricular structures and aortic arch arteries.9-11 One of the dHAND-dependent
genes is the ubiquitin fusion degradation 1–like gene (UFD1L), which is expressed
at high levels during embryogenesis, maps to human chromosome 22, an area called*dHAND  deciduum, heart, autonomic nervous system, neural crest-derived.
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Dthe CATCH region,* and encodes a protein involved in
degradation of ubiquinated proteins. These findings suggest
that UFD1L gene insufficiency is involved in the develop-
ment of congenital heart defects, especially malformations
in the conotruncal region. We hypothesized that the UFD1L




Specimens from 39 patients with BAV (27 male and 12 female,
aged 56.9  18.1 years) and 38 patients with tricuspid atrial valve
(TAV, 25 male and 13 females, aged 61.7  16.1 years) were
analyzed (Table 1). Valve cusps were collected during surgery and
immediately frozen in liquid nitrogen. Only fused leaflets were
used for analysis of gene expression and protein analysis.
None of the patients showed clinical signs characteristic of
22q11.2 syndrome. Fluorescence in situ hybridization analysis was
performed for detection of microdeletion, reverse transcriptase–
polymerase chain reaction for gene expression, and Western blot-
ting for protein analysis.
The study protocol was approved by the institutional ethics
committee. Written, informed consent was obtained from each
patient.
Microdeletion Analysis
For fluorescence in situ hybridization analysis, 3-mL samples of
venous blood collected from 10 of the patients with BAV were
compared with 3-mL samples of venous blood from 10 patients
with TAV. Fluorescence in situ hybridization for the DiGeorge
syndrome critical region on chromosome 22q11.2 was performed
with a dual color probe (N25 LSI/ARSA; Vysis Inc, Downers
Grove, Ill). Slides were prepared according to standard cytogenetic
procedures. The dual color probe allows simultaneous identifica-
tion of both number 22 chromosomes. For each patient, at least 10
Abbreviations and Acronyms
AP-2  activating enhancer-binding protein 2
BAV  bicuspid aortic valve
CATCH  cardiac defect, abnormal facies, thymic
hypoplasia or aplasia and T-cell
deficiency, cleft palate,
hypoparathyroidism, and hypocalcemia
dHAND  deciduum, heart, autonomic nervous
system, neural crest-derived
GAPDH  reduced glyceraldehyde-phosphate
dehydrogenase gene
NF-ATc  nuclear factor of activated T cells
SRY  sex determining region Y–box 4 (SOX4)
TAV  tricuspid aortic valve
TBX1  T-box 1 gene
UFD1L  ubiquitin fusion degradation 1–like gene*CATCH  cardiac defect, abnormal facies, thymic hypoplasia or aplasia and
T-cell deficiency, cleft palate, hypoparathyroidism, and hypocalcemia.
1532 The Journal of Thoracic and Cardiovascular Surgery ● Decmetaphases were scored for possible deletions in the DiGeorge
region. Aberrations of less than 10% in the normal signal pattern
were regarded as artifacts.
UFD1L Gene Expression Analysis
For UFD1L gene expression studies, tissues from 27 patients with
BAV were compared with tissues from 20 patients with TAV.
Total RNA was prepared from 200-mg snap-frozen tissue with
TRIzol (Invitrogen, Karlsruhe, Germany). Reverse transcription
was carried out with 1 g total RNA with the GeneAmp PCR
system 2700 (Applied Biosystems, Darmstadt, Germany) in a
reaction volume of 25 l containing 7.5 mol/L random hexam-
ers, 1 reverse transcription buffer, 220 mol/L of each de-
oxynucleotide triphosphate, 20 U ribonuclease inhibitor, and 50 U
reverse transcriptase. A 2-L portion of complementary DNA was
used for final application to quantify UFD1L messenger RNA.
TaqMan reverse transcriptase–polymerase chain reaction was per-
formed with fluorogenic probe and Universal Master mix on
ABI PRISM 7000 SDS (Applied Biosystems) according to man-
ufacturer instructions. Polymerase chain reaction products were
measured at the threshold cycle at which fluorescence became
detectable above the baseline. Levels of UFD1L messenger RNA
were normalized to those of the reduced glyceraldehyde-phosphate
dehydrogenase gene (GAPDH) and relative to a calibrator. The
relative changes in the gene expression are given by 2CT,
where CT  (CTSample)  (CTCalibrator). Amplification
primers and detection probes were designed for the UFD1L gene
in our laboratory with PrimerExpress software version 2.0 (Ap-
plied Biosystems) to cross intron/exon boundaries. Oligose-
quences are based on those retrieved from the GenBank database
(U64444 for hUFD1L and BC029618 for hGAPDH). Forward
primer 5=-TCC ACA CAG TAC CGC TGC TTC T-3=, reverse
TABLE 1. Patient hemodynamic characteristics, underlying
systemic diseases, and valve morphologic types
BAV TAV
Aortic valve disease
Predominant aortic insufficiency 16 9








Aneurysm of ascending aorta 15 9
Dissection 0 1
Morphologic types of BAV
Raphe between left-right coronary
sinus 38 —
Raphe between right noncoronary
sinus 1 —
Entries represent numbers of patients. BAV, Bicuspid aortic valve; TAV,
tricuspid aortic valve.primer 5=-TCA GAT GTG GAG AAA GGA GGG AA-3=, and
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DTaqMan FAM-MGB probe 5=-TAG CAT GGC CTA ATG
ACA-3= were used to amplify and detect a 77–base pair UFD1L
fragment. The human GAPDH predeveloped TaqMan assay re-
agent VIC-MGB probe (part number 4326317E; Applied Biosys-
tems) was used as endogenous control.
UFD1L Gene Product Analysis
Protein analysis was performed on 12 patients in each group. For
the Western blot, 500 mg valve tissue was homogenized in 300 l
lysis buffer (Cell Signaling Technology, Inc, Beverly, Mass).
sodium dodecylsulfate–polyacrylamide gel electrophoresis was
performed according to the method of Laemmli11a on an 18%
polyacrylamide gel with 50 g tissue-extracted protein loaded per
lane. After electrophoresis, separated proteins were blotted onto an
Immobilon membrane (Millipore [UK] Limited, Watford, United
Kingdom). Nonspecific sites were blocked by a solution containing
5% fat-free milk powder in phosphate-buffered saline solution.
Membranes were incubated with antibody solution containing 1
g/mL anti–human ubiquitin overnight at 37°C (R&D Systems,
Minneapolis, Minn). After five washes with blocking buffer, mem-
branes were incubated with the secondary antibody solution con-
taining a 1:2000 dilution of horseradish peroxidase–conjugated
goat antimouse antibodies. For detection of protein signals, per-
oxidase reaction was carried out by enzyme-linked chemilumines-
The Journal of Thoraciccence (Amersham Biosciences Europe GmbH, Freiburg, Germany).
The polypeptide bands were semiquantified by computerized
blot scanning and measurement of optical density. A positive
control of UFD1L gene product protein was used (Sigma,
Taufkirchen, Germany). In addition we applied the -actin
antibody (Abcam Ltd, Cambridge, United Kingdom) as a load-
ing control antibody.
Statistical Analysis
Statistical analysis was performed with the Statistical Package for
Social Sciences version 9.0 (SPSS GmbH Software, Munich, Ger-
many). Differences among groups were assessed with the Mann-
Whitney U test. The changes in gene expression in the two groups
were compared with analysis of variance. Bonferroni adjustment
was applied for multiple tests.
Results
Microdeletion on Chromosome 22
In all investigated cases, no microdeletion of the critical
CATCH region on chromosome 22, including the UFD1L
gene, was detected (Figure 1, a). Figure 1, b, shows repre-
sentative metaphase and interphase cells from a patient with
Figure 1. a, CATCH region on chromosome 22 and its
important genes, including UFD1L. b, Fluorescence
in situ hybridization study of blood with 22q13.3
(LSI/ARSA) and DiGeorge/VCFS probe. All signals
were present in metaphase and interphase cells of
patient with BAV and showed no microdeletion in
CATCH region. Arrows indicate that the loci are
present on both chromosomes in metaphase and
interphase cells. c, Positive control with 22q11.2
microdeletion. Arrow indicates one chromosome 22
with only one signal of LSI ARSA control probe in
metaphase cell. The second signal is missed, indi-
cating deletion of the 22q11.2 (obtained from Center
for Human Genetics, University of Bremen,
Germany).BAV. Figure 1, c, shows a positive control sample of the
and Cardiovascular Surgery ● Volume 130, Number 6 1533
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DCATCH region deletion (obtained from the Center for Hu-
man Genetics, University of Bremen, Germany).
UFD1L Gene Expression
UFD1L gene expression was significantly decreased in
BAV. The median expression levels in BAV and TAV,
respectively, were 787-fold (maximum 16,845-fold, mini-
mum 7-fold) and 10,887-fold (maximum 52,136-fold, min-
imum 24-fold, P  .001; Figure 2).
UFD1L Gene Product Quantification
The UFD1L gene product protein level was significantly
reduced in BAV (3.9  2.6 optical density units) relative to
TAV (8.4  4.8 optical density units, P  .05; Figure 3).
Discussion
This study shows that BAV is associated with a reduced
UFD1L gene expression. It supports the hypothesis of BAV
as a genetic disorder and also indicates UFD1L as among
the candidate genes warranting further investigation.
BAV is the most common congenital cardiac malforma-
tion, affecting 1% to 2% of the general population.1 BAV
contributes significantly to the cardiovascular health bur-
den. Comprehensive knowledge of the pathogenesis of
BAV may be important for treatment strategies.
A number of mechanisms may be involved, either alone
or combined, in the pathogenesis of BAV. Theoretically,
epigenetic factors during cardiac morphogenesis, such as
fluid forces, may contribute to BAV development in a
Figure 2. Relative UFD1L gene expressions (box plots) in aortic
leaflets from patients with BAV (median 787-fold) and in leaflets
from patients with TAV (median 10,887-fold). Numbers were cal-
culated with 2CT method. Significantly higher level of UFD1L
gene expression was seen in TAV than in BAV (P  .001).manner similar to that of factors resulting in impaired valve
1534 The Journal of Thoracic and Cardiovascular Surgery ● Decfunction, valve stiffness, and opening abnormalities.12 Sev-
eral recent studies have demonstrated that BAV is inherit-
able as part of the whole spectrum of anomalies of the left
ventricular outflow tract. Wessels and colleagues2 even
suggest that all left ventricular outflow tract anomalies,
including BAV, may be caused by a single gene defect.
A number of studies have shown that 22q11.2 deletions
cause a variety of cardiac outflow tract defects.13-15 These
cardiac defects are also seen after neural crest ablation,
suggesting that certain genes controlling neural crest cells
may be involved in the development of cardiac outflow tract
malformations and may map to chromosome 22. The criti-
cal CATCH region of this chromosome consists of many
genes, including the UFD1L and T-box 1 (TBX1) genes.
Yamagishi and associates10 detected the UFD1L gene in all
182 patients with 22q11.2 syndrome in their investigation.
During embryogenesis, the UFD1L gene is highly ex-
pressed in certain tissues. It encodes a component of a
multienzyme complex involved in the degradation of ubiq-
uitin fusion proteins. A downregulation of the UFD1L gene,
hypothetically resulting from an anomalous behavior of
Figure 3. a, UFD1L gene product levels (box plots) in aortic
leaflets from patients with BAV and patients with TAV. b, Levels
of UFD1L gene product protein on Western blot (arrow) in aortic
leaflets from 3 patients with BAV (lanes 2-4) and from 3 patients
with TAV (lanes 5-7), in 1 positive pure control (lane 8), in water
(lane 9), and in two protein markers (lanes 1 and 10). c, Measure-
ment of amount of protein analyzed by Western blotting, with
-actin as loading control antibody. Lanes 1 and 8 are positive
control, lane 9 is water, and lane 10 is protein marker.neural crest cells, may lead to reduced degradation activities
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Dand thus explain in part the hypotheses of Sans-Coma and
associates,16 who demonstrated in Syrian hamsters the fu-
sion of valve cushions as a key factor in the development of
congenital BAV. Furthermore, mouse homolog Ufd1 gene
expression was detected in the cardiac outflow tract at the
same time as neural crest cell condensation, before these
cells transformed into ectomesenchymal cells.
These observations highlight the important role of the
UFD1L gene in the development of ectoderm-derived struc-
tures, including neural crest cells.10,17 These cells have also
been found in developing aortic leaflets,18 pointing to the
UFD1L gene as a candidate for the pathogenesis of BAV. In
our study, no deletion of the critical CATCH region on
chromosome 22, including the UFD1L gene, was found in
any of the patients with BAV. This was not entirely unex-
pected, because a microdeletion would theoretically lead to
more phenotypic abnormalities. We did find, however,
downregulation of the UFD1L gene and consequently di-
minished amounts of its gene product. Our results accord
with the finding that a functional attenuation of chick
UFD1L in cardiac neural crest cells results in an increased
incidence of conotruncal septation defects.14 The exact
mode of downregulation of the UFD1L gene and how it
induces BAV in human beings remain unclear. Some find-
ings implicate the transcription factor AP-2,* which is ac-
tive as a regulator of gene expression during the differen-
tiation and development of neural crest cells.19,20 It is also
involved in the regulation of transforming growth factor
,21 estrogen receptor,22 type IV collagenase,23 insulinlike
growth factor binding 5,24 and many other genes. A sys-
tematic investigation is needed to elucidate the important
biologic functions of AP-2 in the regulation of the UFD1L
gene.
Another gene that maps to the CATCH region involved
in 22q11.2 syndrome and may be involved in the pathogen-
esis of BAV is the TBX1 gene. We measured TBX1 gene
expressions in 10 patients in each group (data not shown),
but we did not find a significant difference between those
with BAV and those with TAV. Whether this is because
TBX1, unlike UFD1L, is not expressed in neural crest cells25
remains to be studied.
Ranger and colleagues26 and de la Pompa and cowork-
ers27 have reported that the targeted dysregulation of the
transcription factor NF-ATc †resulted in selective absence
of the aortic valves, leading to death in utero. A similar
phenotype was observed in SRY (sex determining region
Y)–box 4 (SOX4)–deficient mice.28 Disorders of the latter
transcription factors, however, do not lead to the character-
istic phenotype of fused leaflets seen in BAV.
A limitation of this study is the fact that it demonstrates
only an association, not a causal relationship, between BAV
*AP-2  activating enhancer-binding protein 2.†NF-ATc  activating enhancer-binding protein 2
The Journal of Thoracicand UFD1L downregulation. Whether the relationship is
causal must be determined by in vivo experiments targeting
downregulation of the UFD1L gene in an animal model.
Also, we did not show pedigree analysis of familial clus-
tering explaining a genetic cause of BAV. Furthermore,
only a few neural crest cells could be identified in late fetal
aortic semilunar valves as a result of a reduction in their
numbers caused by death or failure to divide.29 This may
have influenced our results, although the ages of our two
groups were comparable, and we found no correlation be-
tween the age of patients with BAV and the degree of
UFD1L gene expression. In addition, the two groups dif-
fered with regard to the underlying valvular etiology, with
more aortic insufficiencies in the BAV group. Whether this
influenced the gene expression remains unclear, but it seems
rather unlikely because leaflet fusion was the basic pathol-
ogy underlying both stenotic and insufficient valves. Al-
though the genetic pathomechanism of BAV is probably far
more complicated (regarding, for example, accompanying
defects such as coarctation), our findings appear to take the
first steps toward an understanding of the genetic basis of
BAV.
We thank Sven Hauke and Norbert Drieschner for their valu-
able help with the fluorescence in situ hybridization analyses.
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